Cargando…
A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
INTRODUCTION: Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune‐related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. CASE PRESENTATION: The patien...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626353/ https://www.ncbi.nlm.nih.gov/pubmed/36341187 http://dx.doi.org/10.1002/iju5.12532 |
_version_ | 1784822712983617536 |
---|---|
author | Fukunaga, Hiroyuki Sumii, Kenta Kawamura, Shun Okuno, Masato Taguchi, Isao Kawabata, Gaku |
author_facet | Fukunaga, Hiroyuki Sumii, Kenta Kawamura, Shun Okuno, Masato Taguchi, Isao Kawabata, Gaku |
author_sort | Fukunaga, Hiroyuki |
collection | PubMed |
description | INTRODUCTION: Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune‐related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. CASE PRESENTATION: The patient was a 60‐year‐old man with primary lung cancer who was receiving long‐term nivolumab therapy. He was referred to our department due to the sudden onset of glans penile pain and micturition pain. We suspected non‐bacterial cystitis as an immune‐related adverse event caused by nivolumab and were able to treat it by administering prednisolone. While his symptoms and findings on cystoscopy recurred during prednisolone therapy, we were able to treat him again by administering an additional dose of infliximab. CONCLUSION: A few reports have described cases of immune checkpoint inhibitor‐induced cystitis for which prednisolone was effective. This report is the first to describe cystitis as a steroid‐resistant immune‐related adverse event. |
format | Online Article Text |
id | pubmed-9626353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96263532022-11-03 A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab Fukunaga, Hiroyuki Sumii, Kenta Kawamura, Shun Okuno, Masato Taguchi, Isao Kawabata, Gaku IJU Case Rep Case Reports INTRODUCTION: Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune‐related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. CASE PRESENTATION: The patient was a 60‐year‐old man with primary lung cancer who was receiving long‐term nivolumab therapy. He was referred to our department due to the sudden onset of glans penile pain and micturition pain. We suspected non‐bacterial cystitis as an immune‐related adverse event caused by nivolumab and were able to treat it by administering prednisolone. While his symptoms and findings on cystoscopy recurred during prednisolone therapy, we were able to treat him again by administering an additional dose of infliximab. CONCLUSION: A few reports have described cases of immune checkpoint inhibitor‐induced cystitis for which prednisolone was effective. This report is the first to describe cystitis as a steroid‐resistant immune‐related adverse event. John Wiley and Sons Inc. 2022-09-24 /pmc/articles/PMC9626353/ /pubmed/36341187 http://dx.doi.org/10.1002/iju5.12532 Text en © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Reports Fukunaga, Hiroyuki Sumii, Kenta Kawamura, Shun Okuno, Masato Taguchi, Isao Kawabata, Gaku A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
title | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
title_full | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
title_fullStr | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
title_full_unstemmed | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
title_short | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
title_sort | case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626353/ https://www.ncbi.nlm.nih.gov/pubmed/36341187 http://dx.doi.org/10.1002/iju5.12532 |
work_keys_str_mv | AT fukunagahiroyuki acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT sumiikenta acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT kawamurashun acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT okunomasato acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT taguchiisao acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT kawabatagaku acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT fukunagahiroyuki caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT sumiikenta caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT kawamurashun caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT okunomasato caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT taguchiisao caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT kawabatagaku caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab |